Cargando…

Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis

Background: Mainstream application of cancer immunotherapy is hampered by the low response rate of most cancer patients. A novel immunotherapeutic target or a biomarker predicting response to immunotherapy needs to be developed. Guanylate-binding protein 1 (GBP1) is an interferon (IFN)-inducible gua...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yaqi, Wu, Jie, Li, Lan, Zhang, Huibo, Zhang, Haohan, Li, Jing, Zhong, Hao, Lei, Tianyu, Jin, Yan, Xu, Bin, Song, Qibin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867058/
https://www.ncbi.nlm.nih.gov/pubmed/35222540
http://dx.doi.org/10.3389/fgene.2022.820135
_version_ 1784655972437852160
author Zhao, Yaqi
Wu, Jie
Li, Lan
Zhang, Huibo
Zhang, Haohan
Li, Jing
Zhong, Hao
Lei, Tianyu
Jin, Yan
Xu, Bin
Song, Qibin
author_facet Zhao, Yaqi
Wu, Jie
Li, Lan
Zhang, Huibo
Zhang, Haohan
Li, Jing
Zhong, Hao
Lei, Tianyu
Jin, Yan
Xu, Bin
Song, Qibin
author_sort Zhao, Yaqi
collection PubMed
description Background: Mainstream application of cancer immunotherapy is hampered by the low response rate of most cancer patients. A novel immunotherapeutic target or a biomarker predicting response to immunotherapy needs to be developed. Guanylate-binding protein 1 (GBP1) is an interferon (IFN)-inducible guanosine triphosphatases (GTPases) involving inflammation and infection. However, the immunological effects of GBP1 in pan-cancer patients are still obscure. Methods: Using large-scale public data, we delineated the landscape of GBP1 across 33 cancer types. The correlation between GBP1 expression or mutation and immune cell infiltration was estimated by ESTIMATE, TIMER, xCell, and quanTIseq algorithms. GBP1-related genes and proteins were subjected to function enrichment analysis. Clustering analysis explored the relationship between GBP1 expression and anti-tumor immune phenotypes. We assessed the patient’s response to immunotherapy using the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS). Furthermore, we validated the predictive power of GBP1 expression in four independent immunotherapy cohorts. Results: GBP1 was differentially expressed in tumors and normal tissues in multiple cancer types. Distinct correlations existed between GBP1 expression and prognosis in cancer patients. GBP1 expression and mutation were positively associated with immune cell infiltration. Function enrichment analysis showed that GBP1-related genes were enriched in immune-related pathways. Positive correlations were also observed between GBP1 expression and the expression of immune checkpoints, as well as tumor mutation burden (TMB). Pan-cancer patients with higher GBP1 expression were more inclined to display “hot” anti-tumor immune phenotypes and had lower TIDE scores and higher immunophenoscore, suggesting that these patients had better responses to immunotherapy. Patients with higher GBP1 expression exhibited improved overall survival and clinical benefits in immunotherapy cohorts, including the Gide et al. cohort [area under the curve (AUC): 0.813], the IMvigor210 cohort (AUC: 0.607), the Lauss et al. cohort (AUC: 0.740), and the Kim et al. cohort (AUC: 0.793). Conclusion: This study provides comprehensive insights into the role of GBP1 in a pan-cancer manner. We identify GBP1 expression as a predictive biomarker for immunotherapy, potentially enabling more precise and personalized immunotherapeutic strategies in the future.
format Online
Article
Text
id pubmed-8867058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88670582022-02-25 Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis Zhao, Yaqi Wu, Jie Li, Lan Zhang, Huibo Zhang, Haohan Li, Jing Zhong, Hao Lei, Tianyu Jin, Yan Xu, Bin Song, Qibin Front Genet Genetics Background: Mainstream application of cancer immunotherapy is hampered by the low response rate of most cancer patients. A novel immunotherapeutic target or a biomarker predicting response to immunotherapy needs to be developed. Guanylate-binding protein 1 (GBP1) is an interferon (IFN)-inducible guanosine triphosphatases (GTPases) involving inflammation and infection. However, the immunological effects of GBP1 in pan-cancer patients are still obscure. Methods: Using large-scale public data, we delineated the landscape of GBP1 across 33 cancer types. The correlation between GBP1 expression or mutation and immune cell infiltration was estimated by ESTIMATE, TIMER, xCell, and quanTIseq algorithms. GBP1-related genes and proteins were subjected to function enrichment analysis. Clustering analysis explored the relationship between GBP1 expression and anti-tumor immune phenotypes. We assessed the patient’s response to immunotherapy using the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS). Furthermore, we validated the predictive power of GBP1 expression in four independent immunotherapy cohorts. Results: GBP1 was differentially expressed in tumors and normal tissues in multiple cancer types. Distinct correlations existed between GBP1 expression and prognosis in cancer patients. GBP1 expression and mutation were positively associated with immune cell infiltration. Function enrichment analysis showed that GBP1-related genes were enriched in immune-related pathways. Positive correlations were also observed between GBP1 expression and the expression of immune checkpoints, as well as tumor mutation burden (TMB). Pan-cancer patients with higher GBP1 expression were more inclined to display “hot” anti-tumor immune phenotypes and had lower TIDE scores and higher immunophenoscore, suggesting that these patients had better responses to immunotherapy. Patients with higher GBP1 expression exhibited improved overall survival and clinical benefits in immunotherapy cohorts, including the Gide et al. cohort [area under the curve (AUC): 0.813], the IMvigor210 cohort (AUC: 0.607), the Lauss et al. cohort (AUC: 0.740), and the Kim et al. cohort (AUC: 0.793). Conclusion: This study provides comprehensive insights into the role of GBP1 in a pan-cancer manner. We identify GBP1 expression as a predictive biomarker for immunotherapy, potentially enabling more precise and personalized immunotherapeutic strategies in the future. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8867058/ /pubmed/35222540 http://dx.doi.org/10.3389/fgene.2022.820135 Text en Copyright © 2022 Zhao, Wu, Li, Zhang, Zhang, Li, Zhong, Lei, Jin, Xu and Song. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Zhao, Yaqi
Wu, Jie
Li, Lan
Zhang, Huibo
Zhang, Haohan
Li, Jing
Zhong, Hao
Lei, Tianyu
Jin, Yan
Xu, Bin
Song, Qibin
Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title_full Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title_fullStr Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title_full_unstemmed Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title_short Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis
title_sort guanylate-binding protein 1 as a potential predictor of immunotherapy: a pan-cancer analysis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867058/
https://www.ncbi.nlm.nih.gov/pubmed/35222540
http://dx.doi.org/10.3389/fgene.2022.820135
work_keys_str_mv AT zhaoyaqi guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT wujie guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT lilan guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT zhanghuibo guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT zhanghaohan guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT lijing guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT zhonghao guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT leitianyu guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT jinyan guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT xubin guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis
AT songqibin guanylatebindingprotein1asapotentialpredictorofimmunotherapyapancanceranalysis